Get the Stockscreener App
8.91
1.70%
-0.18
After Hours:
8.92
0.010
+0.11%
Arvinas Inc stock is traded at $8.91, with a volume of 517.01K.
It is down -1.70% in the last 24 hours and down -14.41% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$9.09
Open:
$9.09
24h Volume:
517.01K
Relative Volume:
0.58
Market Cap:
$575.53M
Revenue:
$262.60M
Net Income/Loss:
$-80.80M
P/E Ratio:
-7.3267
EPS:
-1.2161
Net Cash Flow:
$-275.70M
1W Performance:
+4.51%
1M Performance:
-14.41%
6M Performance:
-28.06%
1Y Performance:
+37.26%
1-Day Range:
$8.895
$9.179
1-Week Range:
$8.4529
$9.34
52-Week Range:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.92 | 586.50M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas Q1 earnings call highlights - MSN
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Moomoo
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
Wedbush Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $11 - Moomoo
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
BofA Securities Raises Price Target on Arvinas to $16 From $14 - marketscreener.com
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - MSN
Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) Insider Sells 11,108 Shares of Stock - MarketBeat
Arvinas president and CEO Randy Teel sells $95,965 in stock By Investing.com - Investing.com Canada
Arvinas CSO Angela Cacace sells $95,965 in company stock By Investing.com - Investing.com India
Arvinas president and CEO Randy Teel sells $95,965 in stock - Investing.com
Arvinas CSO Angela Cacace sells $95,965 in company stock - Investing.com
Arvinas CFO Andrew Saik sells $110,692 in company shares By Investing.com - Investing.com South Africa
Arvinas CFO Andrew Saik sells $110,692 in company shares - Investing.com
Arvinas (ARVN) CFO sells 11,139 shares to cover RSU taxes - Stock Titan
Arvinas (ARVN) VP Loomis has 1,919 shares sold to cover RSU taxes - Stock Titan
Arvinas (ARVN) CSO share sale covers RSU tax withholding - Stock Titan
Arvinas (ARVN) CMO share sale covers RSU tax withholding - Stock Titan
Automatic tax sale trims Arvinas (NASDAQ: ARVN) CEO share holdings - Stock Titan
BofA raises Arvinas stock price target on Veppanu out-licensing deal By Investing.com - Investing.com South Africa
BTIG raises Arvinas stock price target on commercial partnership By Investing.com - Investing.com India
BofA raises Arvinas stock price target on Veppanu out-licensing deal - Investing.com Nigeria
Goldman Sachs Maintains Arvinas(ARVN.US) With Sell Rating, Maintains Target Price $6 - Moomoo
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ARVN Maintained by Barclays -- Price Target Raised to $20 - GuruFocus
Arvinas anticipates US ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028 - MSN
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):